维持性血液透析患者的微炎症状态与促红细胞生成素低反应性贫血

doi:10.3969/j.issn.1004-583X.2023.10.017

摘要/Abstract

摘要：

补充外源性促红细胞生成素制剂是肾性贫血的重要治疗策略,临床实践中部分患者对促红细胞生成素制剂表现出耐药性,即促红细胞生成素低反应性或抵抗,微炎症状态在这一过程中发挥重要作用。目前,缺氧诱导因子脯氨酰羟化酶抑制剂为肾性贫血管理带来新的机会,其他药物,如新型口服铁剂、铁调素拮抗剂及促炎细胞因子抑制药物等正处于临床各阶段研究,今后有望为慢性肾衰竭并促红细胞生成素低反应性贫血带来新的管理模式。

关键词: 连续性肾脏替代疗法, 贫血, 贫血, 缺铁性, 促红细胞生成素低反应性, 微炎症

中图分类号:

R556

张娟, 田茂露, 查艳. 维持性血液透析患者的微炎症状态与促红细胞生成素低反应性贫血[J]. 临床荟萃, 2023, 38(10): 949-953.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2023.10.017

https://huicui.hebmu.edu.cn/CN/Y2023/V38/I10/949

参考文献 42

[1]	Griffin P. Rodgers. United States Renal Data System. 2022 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2022[DB/OL]. https://usrds-adr.niddk.nih.gov/2022/end-stage-renal-disease/3-clinical-indicators-and-preventive-care.html, 2023-03-10.
[2]	Miyata T, Ueda Y, Horie K, et al. Renal catabolism of advanced glycation end products: The fate of pentosidine[J]. Kidney Int, 1998, 53(2):416-422. pmid: 9461101
[3]	Uribarri J, Del Castillo MD, De La Maza MP, et al. Dietary advanced glycation end products and their role in health and disease[J]. Adv Nutr, 2015, 6(4): 461-473. doi: 10.3945/an.115.008433 pmid: 26178030
[4]	Pageon H, Zucchi H, Rousset F, et al. Glycation stimulates cutaneous monocyte differentiation in reconstructed skin in vitro[J]. Mech Ageing Dev, 2017, 162: 18-26. doi: S0047-6374(16)30135-X pmid: 28163107
[5]	Odetti P, Cosso L, Pronzato MA, et al. Plasma advanced glycosylation end-products in maintenance haemodialysis patients[J]. Nephrol Dial Transplant, 1995, 10(11):2110-2113.
[6]	于敏, 王姣, 史耀勋, 等. 慢性肾衰竭微炎症状态发生机制的研究进展[J]. 中华医院感染学杂志, 2010, 20(10):1498-1500.
[7]	Xu G, Luo K, Liu H, et al. The progress of inflammation and oxidative stress in patients with chronic kidney disease[J]. Ren Fail, 2015, 37(1): 45-49. doi: 10.3109/0886022X.2014.964141 pmid: 25375354
[8]	Syed-Ahmed M, Narayanan M. Immune dysfunction and risk of infection in chronic kidney disease[J]. Adv Chronic Kidney Dis, 2019, 26(1): 8-15. doi: 10.1053/j.ackd.2019.01.004 URL
[9]	Ekdahl KN, Soveri I, Hilborn J, et al. Cardiovascular disease in haemodialysis: Role of the intravascular innate immune system[J]. Nat Rev Nephrol, 2017, 13(5): 285-296. doi: 10.1038/nrneph.2017.17 pmid: 28239169
[10]	Bossola M, Sanguinetti M, Scribano D, et al. Circulating bacterial-derived DNA fragments and markers of inflammation in chronic hemodialysis patients[J]. Clin J Am Soc Nephrol, 2009, 4(2): 379-385. doi: 10.2215/CJN.03490708 URL
[11]	Wang F, Zhang P, Jiang H, et al. Gut bacterial translocation contributes to microinflammation in experimental uremia[J]. Dig Dis Sci, 2012, 57(11): 2856-2862. doi: 10.1007/s10620-012-2242-0 URL
[12]	Fraenkel PG. Anemia of inflammation: A review[J]. Med Clin North Am, 2017, 101(2): 285-296. doi: 10.1016/j.mcna.2016.09.005 URL
[13]	Steinbicker AU, Sachidanandan C, Vonner AJ, et al. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation[J]. Blood, 2011, 117(18): 4915-4923. doi: 10.1182/blood-2010-10-313064 pmid: 21393479
[14]	Yan Z, Xu G. A novel choice to correct inflammation-induced anemia in CKD:oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat[J]. Front Med (Lausanne), 2020, 6(7): 393.
[15]	Ganz T, Longo DL. Anemia of Inflammation[J]. NewEngla nd Journal of Medicine, 2019, 381(12): 1148-1157.
[16]	De Oliveira, Junior WV, Sabino AP, et al. Inflammation and poor response to treatment with erythropoietin in chronic kidney disease[J]. J Bras Nefrol, 2015, 37(2): 255-263. doi: 10.5935/0101-2800.20150039 pmid: 26154647
[17]	Souma T, Yamazaki S, Moriguchi T, et al. Plasticity of renal erythropoietin-producing cells governs fibrosis[J]. J Am Soc Nephrol, 2013, 24(10):1599-1616. doi: 10.1681/ASN.2013010030 pmid: 23833259
[18]	Fujii J, Homma T, Kobayashi S, et al. Erythrocytes as a preferential target of oxidative stress in blood[J]. Free Radic Res, 2021, 55(5): 562-580.
[19]	Hsu SP, Chiang CK, Yang SY, et al. Nacetylcysteine for the management of anemia and oxidative stress in hemodialysis patients[J]. Nephron Clinical Practice, 2010, 116(3): c207-c216. doi: 10.1159/000317201 URL
[20]	Shepshelovich D, Rozen-Zvi B, Avni T, et al. Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis[J]. Am J Kidney Dis, 2016, 68(5): 677-690. doi: S0272-6386(16)30125-1 pmid: 27321965
[21]	Drueke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease[J]. Circulation, 2002, 106(17): 2212-2217. doi: 10.1161/01.cir.0000035250.66458.67 pmid: 12390950
[22]	Stefanova D, Raychev A, Arezes J, et al. Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron[J]. Blood, 2017, 130(3): 245-257. doi: 10.1182/blood-2017-03-772715 pmid: 28465342
[23]	Shah AA, Donovan K, Seeley C, et al. Risk of infection associated with administration of intravenous iron[J]. JAMA, 2021, 4(11):e2133935.
[24]	Li X, Cole SR, Kshirsagar AV, et al. Safety of Dynamic Intravenous Iron Administration Strategies in Hemodialysis Patients[J]. Clinical Journal of the American Society of Nephrology, 2019, 14(5): 728-737. doi: 10.2215/CJN.03970318 pmid: 30988164
[25]	汤莹, 杜光, 孙秋雁. 缺铁性贫血临床药物治疗进展[J]. 中国医院药学杂志, 2022, 23:2560-2566.
[26]	Pergola PE, Kopyt NP. Oral ferric maltol for the treatment of iron-deficiency anemia in patients with CKD: A randomized trial and open-label extension[J]. Am J Kidney Dis, 2021, 78(6): 846-856. doi: 10.1053/j.ajkd.2021.03.020 pmid: 34029682
[27]	Kaplan JM, Sharma N, Dikdan S. Hypoxia-inducible factor and its role in the management of anemia in chronic kidney disease[J]. Int J Mol Sci, 2018, 19(2):389. doi: 10.3390/ijms19020389 URL
[28]	Chen N, Hao C, Liu BC, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis[J]. N Engl J Med, 2019, 381(11): 1011-1022. doi: 10.1056/NEJMoa1901713 URL
[29]	Chen N, Hao C, Peng X, et al. Roxadustat for Anemia in patients with kidney disease not receiving dialysis[J]. N Engl J Med, 2019, 381(11): 1001-1010. doi: 10.1056/NEJMoa1813599 URL
[30]	Besarab A, Provenzano R, Hertel J, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients[J]. Nephrol Dial Transplant, 2015, 30(10): 1665-1673. doi: 10.1093/ndt/gfv302 URL
[31]	周任, 陈亚婷, 张永. 罗沙司他治疗血液透析肾性贫血患者有效性和安全性的Meta分析[J]. 临床荟萃, 2022, 37(4):305-310.
[32]	Su X, Xie Y, Zhang J, et al. HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis[J]. Cell Death Dis, 2022, 13(10):861. doi: 10.1038/s41419-022-05304-8 pmid: 36209275
[33]	D'arrigo G, Baggetta R, Tripepi G, et al. Effects of vitamin e-coated versus conventional membranes in chronic hemodialysis patients: A systematic review and meta-analysis[J]. Blood Purif, 2017, 43(1-3): 101-122. doi: 10.1159/000453444 URL
[34]	Susantitaphong P, Riella C, Jaber BL. Effect of ultrapure dialysate on markers of inflammation, oxidative stress, nutrition and anemia parameters: A meta-analysis[J]. Nephrol Dial Transplant, 2013, 28(2): 438-446. doi: 10.1093/ndt/gfs514 URL
[35]	Zhang Y, Mei CL, Rong S, et al. Effect of the combination of hemodialysis and hemoperfusion on clearing advanced glycation end products: A prospective, randomized, two-stage crossover trial in patients under maintenance hemodialysis[J]. Blood Purif, 2015, 40(2): 127-132. doi: 10.1159/000376604 URL
[36]	Macdougall IC, Bhandari S, White C, et al. Intravenous iron dosing and infection risk in patients on hemodialysis: A prespecified secondary analysis of the PIVOTAL trial[J]. J Am Soc Nephrol, 2020, 31(5): 1118-1127. doi: 10.1681/ASN.2019090972 pmid: 32253271
[37]	Hasegawa T, Zhao J, Fuller DS, et al. Erythropoietin hyporesponsiveness in dialysis patients: Possible role of statins[J]. Am J Nephrol, 2017, 46(1): 11-17. doi: 10.1159/000477217 pmid: 28564644
[38]	Zhu Y, Tang Y, He H, et al. Gut Microbiota correlates with clinical responsiveness to erythropoietin in hemodialysis patients with anemia[J]. Front Cell Infect Microbiol, 2022, 22(12): 919352.
[39]	Sagar P, Angmo S, Sandhir R, et al. Effect of hepcidin antagonists on anemia during inflammatory disorders[J]. Pharmacol Ther, 2021, 226: 107877. doi: 10.1016/j.pharmthera.2021.107877 URL
[40]	Schwoebel F, Van Eijk LT, Zboralski D, et al. The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys[J]. Blood, 2013, 121(12): 2311-2315. doi: 10.1182/blood-2012-09-456756 pmid: 23349391
[41]	Van Eijk LT, John AS, Schwoebel F, et al. Effect of the antihepcidin spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans[J]. Blood, 2014, 124(17): 2643-2646. doi: 10.1182/blood-2014-03-559484 pmid: 25163699
[42]	Renders L, Budde K, Rosenberger C, et al. First-in-human phase i studies of prs-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis[J]. PLoS One, 2019, 14(3): e0212023. doi: 10.1371/journal.pone.0212023 URL

维持性血液透析患者的微炎症状态与促红细胞生成素低反应性贫血

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 42

相关文章 15

编辑推荐

Metrics

本文评价

[1]	谷翠红, 王阳, 林丽, 王丽红, 张志华. 抗胸腺细胞球蛋白联合环孢素A治疗儿童重型再生障碍性贫血诱发毛细血管渗透综合征1例[J]. 临床荟萃, 2023, 38(9): 819-322.
[2]	代菁, 陈华茜. 血液透析患者自发性肾破裂1例并文献复习[J]. 临床荟萃, 2023, 38(12): 1107-1111.
[3]	朱卫健, 何颖, 黄慕芳, 付社竹, 王小琪, 李志新, 陈丽君, 李小亮. 沙利度胺治疗β-地中海贫血外周血miR-223-3p水平变化及临床价值[J]. 临床荟萃, 2022, 37(6): 515-518.
[4]	张宏涛, 王志奎. 单中心维持性腹膜透析患者肾性贫血现况及相关因素分析[J]. 临床荟萃, 2022, 37(12): 1099-1103.
[5]	施惠宣，陈国兵，陈先睿. 川崎病合并G6PD缺乏症1例并文献复习[J]. 临床荟萃, 2020, 35(6): 555-557.
[6]	李姣1a，张亚平1b，张瑞1a，岳晓乐1a，史敏1a，谭延伟2. 妊娠期铁代谢与铁调节蛋白调控的研究进展[J]. 临床荟萃, 2019, 34(11): 1026-1029.
[7]	常英军1，魏辉2，任金海3. 2018血液病年度进展[J]. 临床荟萃, 2019, 34(1): 17-22.
[8]	龙昌柱1，田丽娜1，袁静2，张祖隆3. 铁调素及其调节研究进展[J]. 临床荟萃, 2018, 33(4): 357-360,364.
[9]	王泽凯，胡志娟，董春霞，牛凯，刘冰. 血浆ghrelin与慢性肾脏病并发症[J]. 临床荟萃, 2018, 33(10): 849-853.
[10]	杨冰雪，程单凤，邱晨希，廖建荣，刘庭波. 环孢素A联合雄激素与单用雄激素治疗国人再生障碍性贫血疗效及安全性分析[J]. 临床荟萃, 2018, 33(10): 889-896,903.
[11]	穆静1，杨文凯1，陈虹2，叶新华2，康曦光2. 兰州市及东乡县6～12岁缺铁性贫血儿童体格发育及健康状况分析[J]. 临床荟萃, 2017, 32(7): 595-598.
[12]	赵霞，郭馨，王嵘，张东成. 生血宁治疗维持性腹膜透析患者的临床观察[J]. 临床荟萃, 2016, 31(9): 1015-1018.
[13]	李杰,杨洁,张晓霞,袁军,王超,郝洪岭. 高血压、水肿、蛋白尿、贫血[J]. 临床荟萃, 2016, 31(6): 679-682.
[14]	温树鹏,杨琳. 慢性肾脏病贫血的规范化治疗[J]. 临床荟萃, 2016, 31(6): 636-640.
[15]	郭晓楠. 贫血的识别及初步处理[J]. 临床荟萃, 2016, 31(3): 336-336.